Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia.

Shapiro RM, Lazo-Langner A.

BMC Hematol. 2018 Jan 31;18:3. doi: 10.1186/s12878-017-0094-8. eCollection 2018.

2.

Treatment with a DNA methyltransferase inhibitor feminizes zebrafish and induces long-term expression changes in the gonads.

Ribas L, Vanezis K, Imués MA, Piferrer F.

Epigenetics Chromatin. 2017 Dec 8;10(1):59. doi: 10.1186/s13072-017-0168-7.

3.

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy.

Prebet T, Cluzeau T, Park S, Sekeres MA, Germing U, Ades L, Platzbecker U, Gotze K, Vey N, Oliva E, Sugrue MM, Bally C, Kelaidi C, Al Ali N, Fenaux P, Gore SD, Komrokji R.

Oncotarget. 2017 Jun 14;8(47):81926-81935. doi: 10.18632/oncotarget.18477. eCollection 2017 Oct 10.

4.

Can we consider discontinuation of hypomethylating agents in patients with myelodysplastic syndrome : a retrospective study from The Korean Society of Hematology AML/MDS Working Party.

Kim DJ, Lee HS, Moon JH, Sohn SK, Kim HJ, Cheong JW, Jo DY, Kim H, Lee H, Bang SM, Lee WS, Park Y, Lee MH, Lee JH, Bae SH, Kim MK; Korean Society of Hematology AML/MDS Working Party.

Oncotarget. 2017 May 29;8(45):79414-79424. doi: 10.18632/oncotarget.18258. eCollection 2017 Oct 3.

5.

HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications.

Harada T, Ohguchi H, Grondin Y, Kikuchi S, Sagawa M, Tai YT, Mazitschek R, Hideshima T, Anderson KC.

Leukemia. 2017 Dec;31(12):2670-2677. doi: 10.1038/leu.2017.144. Epub 2017 May 11.

6.

Decitabine treatment sensitizes tumor cells to T-cell-mediated cytotoxicity in patients with myelodysplastic syndromes.

Zhang Z, He Q, Tao Y, Guo J, Xu F, Wu LY, Zhao YS, Wu D, Zhou LY, Su JY, Song LX, Xiao C, Li X, Chang CK.

Am J Transl Res. 2017 Feb 15;9(2):454-465. eCollection 2017.

7.

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.

Pleyer L, Döhner H, Dombret H, Seymour JF, Schuh AC, Beach CL, Swern AS, Burgstaller S, Stauder R, Girschikofsky M, Sill H, Schlick K, Thaler J, Halter B, Machherndl Spandl S, Zebisch A, Pichler A, Pfeilstöcker M, Autzinger EM, Lang A, Geissler K, Voskova D, Sperr WR, Hojas S, Rogulj IM, Andel J, Greil R.

Int J Mol Sci. 2017 Feb 15;18(2). pii: E415. doi: 10.3390/ijms18020415.

8.
9.

Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study.

Azad NS, El-Khoueiry A, Yin J, Oberg AL, Flynn P, Adkins D, Sharma A, Weisenberger DJ, Brown T, Medvari P, Jones PA, Easwaran H, Kamel I, Bahary N, Kim G, Picus J, Pitot HC, Erlichman C, Donehower R, Shen H, Laird PW, Piekarz R, Baylin S, Ahuja N.

Oncotarget. 2017 May 23;8(21):35326-35338. doi: 10.18632/oncotarget.15108.

10.

Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy.

Prebet T, Toma A, Cluzeau T, Sekeres MA, Vey N, Park S, Al Ali N, Sugrue MM, Komrokji R, Fenaux P, Gore SD.

Oncotarget. 2017 Jun 6;8(23):37866-37874. doi: 10.18632/oncotarget.15200.

11.

Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes.

Navada SC, Silverman LR.

Ther Adv Hematol. 2017 Jan;8(1):21-27. doi: 10.1177/2040620716674677. Epub 2016 Oct 20. Review.

12.

Unusual lower back pain with monocytosis: A case report.

Wu SC, Huang TC, Yu WY, Wu YY.

Oncol Lett. 2016 Nov;12(5):4048-4050. Epub 2016 Sep 26.

13.

Demethylating Agents in the Treatment of Cancer.

Howell PM, Liu Z, Khong HT.

Pharmaceuticals (Basel). 2010 Jul 2;3(7):2022-2044. Review.

14.

Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.

Ball B, Zeidan A, Gore SD, Prebet T.

Leuk Lymphoma. 2017 May;58(5):1022-1036. doi: 10.1080/10428194.2016.1228927. Epub 2016 Sep 21. Review.

15.

Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.

Zhao X, Tian X, Kajigaya S, Cantilena CR, Strickland S, Savani BN, Mohan S, Feng X, Keyvanfar K, Dunavin N, Townsley DM, Dumitriu B, Battiwalla M, Rezvani K, Young NS, Barrett AJ, Ito S.

Br J Haematol. 2016 Nov;175(3):427-439. doi: 10.1111/bjh.14244. Epub 2016 Jul 19.

16.

Expression of the chemokine CXCL14 and cetuximab-dependent tumour suppression in head and neck squamous cell carcinoma.

Kondo T, Ozawa S, Ikoma T, Yang XY, Kanamori K, Suzuki K, Iwabuchi H, Maehata Y, Miyamoto C, Taguchi T, Kiyono T, Kubota E, Hata RI.

Oncogenesis. 2016 Jul 11;5(7):e240. doi: 10.1038/oncsis.2016.43.

17.

Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies.

Fratta E, Montico B, Rizzo A, Colizzi F, Sigalotti L, Dolcetti R.

Oncotarget. 2016 Aug 30;7(35):57327-57350. doi: 10.18632/oncotarget.10033. Review.

18.

Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.

Yun S, Vincelette ND, Abraham I, Robertson KD, Fernandez-Zapico ME, Patnaik MM.

Clin Epigenetics. 2016 Jun 14;8:68. doi: 10.1186/s13148-016-0233-2. eCollection 2016. Review.

19.

A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.

Thépot S, Ben Abdelali R, Chevret S, Renneville A, Beyne-Rauzy O, Prébet T, Park S, Stamatoullas A, Guerci-Bresler A, Cheze S, Tertian G, Choufi B, Legros L, Bastié JN, Delaunay J, Chaury MP, Sanhes L, Wattel E, Dreyfus F, Vey N, Chermat F, Preudhomme C, Fenaux P, Gardin C; Groupe Francophone des Myélodysplasies (GFM).

Haematologica. 2016 Aug;101(8):918-25. doi: 10.3324/haematol.2015.140988. Epub 2016 May 26.

20.

The blind men and the AML elephant: can we feel the progress?

Tauro S.

Blood Cancer J. 2016 May 13;6:e424. doi: 10.1038/bcj.2016.33. Review.

Supplemental Content

Support Center